Related Experiment Videos
Chlamydial pneumonitis and its serodiagnosis in infants
Insights
Enzyme immunoassay (EIA) using the major outer membrane protein (MOMP) of Chlamydia trachomatis is a sensitive and specific method for detecting IgM antibodies in infants with suspected chlamydial pneumonitis.
Area of Science:
- Pediatric Infectious Diseases
- Microbiology
- Immunology
Background:
- Chlamydial pneumonitis is a significant respiratory infection in infants.
- Accurate and efficient diagnostic methods are crucial for timely treatment.
- Current diagnostic methods may have limitations in sensitivity or specificity.
Purpose of the Study:
- To evaluate the efficacy of enzyme immunoassay (EIA) using different antigens for detecting Chlamydia trachomatis antibodies in infants.
- To compare EIA performance against the standard immunofluorescence test (I/RB IFAT).
- To assess the potential of EIA for automated screening of infant respiratory infections.
Main Methods:
- Sera from 30 infants with suspected chlamydial pneumonitis were tested.
- Enzyme immunoassay (EIA) was performed using three antigens: reticulate bodies (RB), major outer membrane protein (MOMP), and Salmonella Re LPS.
- The immunofluorescence test (I/RB IFAT) served as the standard method for detecting IgM antibodies.
Main Results:
- The MOMP EIA demonstrated sensitivity and specificity comparable to the I/RB IFAT for detecting IgM antibodies.
- MOMP EIA identified IgM antibodies in 15 sera, while I/RB IFAT identified them in 16.
- RB EIA detected antibodies in 17 sera, and Re LPS EIA in 2 sera.
Conclusions:
- The MOMP EIA is a sensitive and specific method for diagnosing chlamydial pneumonitis in infants.
- Automated EIA offers potential for widespread screening of infants with respiratory symptoms.
- Further validation may support EIA as a primary diagnostic tool for infant Chlamydia infections.
Abstract:
Sera from 30 infants with suspected chlamydial pneumonitis were studied by enzyme immunoassay (EIA) with three antigens: reticulate bodies (RB), purified major outer membrane protein ( MOMP ) of Chlamydia trachomatis strain L2, and purified lipopolysaccharide from Re mutants of Salmonella (Re LPS), which shows complete cross-reaction with chlamydial glycolipid. The immunofluorescence test (I/RB IFAT), which detected IgM antibodies (titer of greater than or equal to 1:64) in 16 patients whose clinical picture was consistent with chlamydial pneumonitis, was the standard method. EIA measured IgM antibodies to the purified antigens but not to RB; 15 sera were positive with the MOMP antigen and two with the Re LPS antigen. High-titered IgG antibodies were detected by I/RB IFAT in 15 and by MOMP EIA in 13 of the 30 sera. By the RB EIA, 17 sera were positive. The MOMP EIA was thus as sensitive and specific as the I/RB IFAT. Because the EIA can be automated, it would make possible the screening of all children younger than six months of age with respiratory-tract symptoms and IgM antibodies to Chlamydia.